Head-to-head · free
Alnylam Pharmaceuticals vs GSAT
ALNY vs GSAT — return on capital, cash generation, margins and balance sheet side by side.
ALNY
6 / 7
measures where ALNY leads
GSAT
1 / 7
measures where GSAT leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | ALNY · FY2025 | GSAT · FY2025 |
|---|---|---|
| Revenue | $3.7B | $273.0M |
| Net income | (18.3M) | (8.7M) |
| Revenue growth (yearly, multi-year) | 44.8% | 21.7% |
| Free cash flow | $465.4M | — |
| Free cash flow margin | 12.5% | — |
| Net cash / (debt) | — | — |
| ROIC | 28.4% | — |
| Return on equity | 73.3% | -5.4% |
| Gross margin | 81.6% | 64.8% |
| Operating margin | 13.5% | 5.4% |
| Net debt / EBITDA | -1.17x | 0.38x |
Figures are as reported by each company; latest fiscal year shown.
Where Alnylam Pharmaceuticals's cash went (FY2025)
- Capital spending
- $58.7M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where GSAT's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free